ReNeuron
ReNeuron is a UK-based stem cell research company whose shares are listed on the Alternative Investment Market. Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.
| Company type | Public company |
|---|---|
| LSE: RENE | |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
Key people | chairman = Trevor Jones |
| Website | reneuron.com |
ReNeuron is testing the effects of neural stem cells on spinal cords for neuroregeneration.[1] They are also testing the use of fetal stem cells on stroke patients.[2]
References
- Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
- "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.